CANCER curable platinum 

 

In 1969, Rosenberg and Van Camp showed high antitumor activity with complexes cis - [Pt (NH3) 2Cl2], cis - [Pt (NH3) 2Cl4] [Pt en Cl2] and [Pt en Cl4] on sarkome180 and leukemia L 1210. Their discovery was confirmed when it was discovered antitumor activity of other compounds of platinum, palladium, rhodium, ruthenium, iridium, which has led to an intensive screening of the substances. In cancer chemotherapy, a new class of anticancer drugs is a complex metal compounds, and in bioinorganic chemistry is developing a new area - the synthesis and study of complex compounds as potential anticancer drugs. 

 

The first and most important to date, representatives of a new class of anticancer drugs were complex compounds of platinum. 

 Currently, the most studied first open a new class of antitumor compounds cis - dihlorodiammin - platinum (DDP) A variety of types of tumors in the animals used in the screening indicates that the platinum drugs have a broad spectrum of antitumor action. DDP is active against tumors of various origins: spontaneous, transplantable, induced by viruses and chemical carcinogens. Since 1971, DDP in clinical trials. Studies at 28 kinds of tumors, with the participation of about two thousand patients have shown that it is characterized by a broad spectrum of activity against human tumors and is effective in melanoma, lymphomas, and tumors of the testis. 

 It should be noted that platinum drugs differ from other anticancer compounds effective in treating solid tumors. Platinum complexes are effective in treating tumors with acquired resistance to other agents. It is noted that not only cure animals, but also save a considerable time (11 months) immunity to reinfection. The main drawback of the DCF of its high toxicity. Studies in animals and in clinical practice have shown that it acts primarily on kidney, bone marrow and the gastrointestinal tract. In addition, people have recognized it at the hearing. Although the majority of patients after cessation of treatment and function of organs 

 normalized, but the adverse side effects prevented its widespread use in the clinic. 

  Recent clinical trials of DDP connected with the search for ways to reduce its toxicity and mode of application in combination therapy. Although the DCF first of a new class of drugs, which started in clinical trials, now there are compounds with better antitumor properties. In the literature there is evidence of such compounds of platinum. Among these complexes with known structure, the rest belong to platinum Cygne, composition and chemical structure of which is not installed. 

  Platinum blue are promising series of antitumor drugs. It is shown that they possess a wide spectrum of antitumor action. They are readily soluble in water, low toxicity. The mechanism of action of platinum drugs on the biochemical level. It is shown that the active platinum drugs inhibit the synthesis of DNA and do not affect the synthesis of RNA, proteins and DNA precursors, as well as on their transport through cell membranes. Inactive drugs in small doses does not affect the processes of biosynthesis in cells, and in big acts as a powerful poison, suppressing all biological processes. 

 

 Along with the above classes of drugs were conducted in parallel work on the creation of drugs - activators of the immune system. The best known among this class of Interleukin-2 (IL 2). 

 This class of drugs shortcomings of previous classes in the sense of a toxic effect on the organism, but, unfortunately, is ineffective and uzkoizbiratelen. 

 

TASK 

 

 Before the creators, taking into account all of the above, has been tasked to establish a drug, devoid of the shortcomings described above classes and the preservation of their merits. Similar attempts in recent years have taken place. 

 

 For example the drug "Viturid" showed very good efficiency, but unfortunately has a low stability of the terminal stages of cancer and, indeed, fit mostly for use in very early stages of the disease. 

 

 "Tsikutin" - this is the second drug is a new generation, made up of biologically active substances plant "milestones poisonous» - (cikuta vitrosa) 

 

 The spectrum of this drug, as antitumor agents, is very broad. It can be applied to the first and second stages of cancer. This eliminates the option of surgical intervention, as well as the use of chemotherapy and radiotherapy. However, the development of this drug is not a lot because of the complexity of synthesis, as well as limitations in the original raw material. Unfortunately with the development of animal milestones poisonous systematically destroyed, as grazing cattle perished from poisoning. 

  In studying the problem of finding a new drug was analyzed causes of these high performance products. response was found creators of a new drug «PLATINUS» cause cancer and antitumor activity is the presence of certain complexes in the composition, which is - the basis of biochemical systems. Therefore, the creators paid attention to the various natural compounds with the properties of complexes. 

  Analysis of published data showed that all necessary requirements are satisfied by some acid salts. 

  It has long been known that some substances are not a random product chain postmortem organic (plant and animal) remains, but a necessary link in the evolution, the most important factor of stability in life processes. Therefore, the main active principle of the drug were chosen some natural salts synthesized in PLATINUS. Next, set mielodepressivnogo absence of a sufficiently high doses PLATINUS. Lack of oppression blood distinguishes this drug from the majority of modern antitumor agents. 

 

 PLATINUS Immunotoxic has no effect. 

 

COMPOSITION, PROPERTIES AND OPERATION 

 

PLATINUS 

 

Contents: set of biologically active substances derived from various types of wood with the salts of platinum (Pt) 

 

Composition and effect: The drug is a liquid dark - brown, containing from 1 to 7 percent of platinum, with a specific taste and smell. Number of sterile product is 300 units Bioeffects in one bottle or three doses. 

 

 In intramuscular or rectal administration, the complex rapidly accumulates in tumor tissue, providing an active component of the drug directly to cancer cells. The possibility of such a manifestation of the complex is provided by Crown - effect. Effects of the latter (Crown - effect) allows the reduction from 80% (sinkers) to 1 - 5% (Bioeffects). 

 

 In addition, having a large number of covalent bonds - active connections, the solution reacts with nucleophilic centers of protein molecules causing the process bifunctional alkylation unit in the gene of the tumor tissue. As a result, long disturbed DNA synthesis, blocking occurs metoticheskogo cycle, as well as enzymatic systems of cancer cells, which leads to their death. 

 

 The ability of drugs to cause regression of tumors and their metastases also connected with the immunostimulatory effect of the drug. 

 

 After the introduction into the body, except the above-described actions, the drug significantly activates endorphinergic system, as having a profound impact on the hypothalamus. 

 

 Increasing concentration of endorphins in the body, in particular - endorphin, greatly activates the single "authority" of immunity (ie, the system of immune response) to develop a mikrofagov called interleukin 1 (Il - 1), produce the growth factor for B - cell Interleukin - 2 (il - 2). Il - 2 activates the activity of T - lymphocytes-killers, as well as the production of gamma-interferon. Last (gamma-interferon) stimulates the activity of anticancer activity of macrophages and lymphocytes-killers (T-killers). 

 

  In addition to the above properties of a drug binds well heavy metal ions and toxins of plant origin, forming with them complex compounds, which eliminates the kidneys and intestines. 

 

Its ability to demonstrate the properties of the drug radioprotector, very much not giving this as a standard-issue drug cystamine. 

 

Indications 

 

  All types of cancer, intoxications of various origins, radiation sickness, 1 -4 degrees, immunodifitsitnoe state of the organism. 

 

 Side effects 

 

Very rarely there was a slight increase in temperature., As in rare cases have been seen no severe pain in the field of direct influence on the tumor at the earliest - the second injection of the drug (which in itself signals the beginning of the effect of the drug to the tumor) 

 The effect of habituation is not installed. 

 

  During the course of treatment the introduction of hormonal drugs is prohibited. 

 

Features drug 

 

 With the introduction of a triple dose of 6 ml antipain possible long-term effect in this period of possible cancellation of analgesics. 

 

  For treatment of lung cancer is necessary to use It is highly bogul'nik swamp or other extraordinary means.